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Abstract
Background: Human trichomoniasis caused by Trichomonas vaginalis is one of the most common sexually transmitted
diseases with more than 200 million cases worldwide. It has caused a series of health problems to patients. For
prevention and control of infectious diseases, vaccines are usually considered as one of the most cost-efficient
tools. However, until now, work on the development of T. vaginalis vaccines is still mainly focused on the
screening of potential immunogens. Alpha-actinin characterized by high immunogenicity in T. vaginalis was
suggested as a promising candidate. Therefore, the purpose of this study was to evaluate the protective potency
of recombinant α-actinin against T. vaginalis infection in a mouse intraperitoneal model.
Methods: Two selected coding regions of α-actinin (ACT-F, 14–469 aa and ACT-T, 462–844 aa) amplified from
cDNA were cloned into pET-32a (+) expression vector and transfected into BL21 cells. After induction with IPTG
and purification with electroelution, the two recombinant fusion proteins were emulsified in Freund’s adjuvant
(FA) and used to immunize BALB/C mice. Following intraperitoneal inoculation with T. vaginalis, the survival rate
of mice was monitored for the assessment of protective potency. After immunization, the antibody level in
mouse serum was assessed by ELISA, splenocyte proliferation response was detected with CCK8 and cytokines in
the supernatant of splenocytes were quantified with a cytometric bead-based assay.
Results: We successfully obtained purified ACT-F (70.33 kDa) and ACT-T (61.7kDa). Both recombinant proteins
could provide significant protection against T. vaginalis challenge, especially ACT-T (with 100% protection within
one month). Meanwhile, high levels of specific total IgG and subtypes (IgG1 > IgG2a) were detected in sera from
the immunized mice. Our results also revealed a statistically significant increase in splenocyte proliferation and
related cytokine (IFN-γ, IL-6, IL-17A and IL-10) production after repeated stimulation with the corresponding
antigens in vitro.
Conclusions: Immunization with both ACT-F and ACT-T could confer partial to complete protection and trigger
strong Th1/Th2 mixed humoral and cellular immune responses in the mouse host. This suggested that
recombinant α-actinin subunit antigens may be promising vaccine candidates against trichomoniasis.
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Background
Trichomoniasis is one of the most common worldwide
sexually transmitted illnesses. It is caused by Trichomonas
vaginalis (TV) which is a facultative anaerobic flagellated
parasite. It was estimated by WHO that 276 million
people were infected with T. vaginalis globally in the age
range from 15 to 49 in 2008 [1] and this had increased by
11% compared to 2005 [2]. The huge number of patients
with trichomoniasis suggest that there is an urgent
requirement to increase public health education and to
provide proper protection.
In general, T. vaginalis resides in the female genital
tract, causing vaginitis, urethritis and cervicitis [3]. It
can also cause post-abortion infection, premature labour
and complications caused by underweight offspring
[4, 5]. Women infected with trichomonas are often
asymptomatic, while about one-third of them may develop
symptomatic infection within 6 months [6]. Men infected
with T. vaginalis are mostly asymptomatic or show mild
symptoms making them unaware of the parasite infection.
Consequently, being carriers, men can transmit the para-
site to their partners during sex [7]. Although T. vaginalis
usually only causes mild symptoms in men, chronic infec-
tion still results in chronic inflammatory stimulation if left
without proper treatment. Interestingly, it has been
demonstrated that T. vaginalis infection is associated with
aggressive prostate cancer [8, 9]. In addition, many reports
have indicated that T. vaginalis infection could signifi-
cantly increase the risk of transmission of human im-
munodeficiency viruses (HIV) [6, 10] and hepatitis viruses
[11]. It has also been suggested to be associated with
cervical cancer [12].
For clinical treatment of trichomoniasis, metronida-
zole is a widely used and effective compound. However,
it may not be suitable for use in pregnant women as it is
mutagenic in bacteria, carcinogenic in mice and, with
the ability to cross the placenta, may result in teratogen-
icity in the fetus [13, 14]. Additionally, a gradual increase
in the prevalence of metronidazole-resistant T. vaginalis
strains has been reported during clinical treatment [7].
Therefore, an effective alternative to chemically synthe-
sized compounds is urgently needed.
Besides using synthesized compounds for the treat-
ment of T. vaginalis infection, vaccination is suggested
as a possible effective way to protect against pathogen
infection. To our knowledge, the priority to develop a
vaccine against T. vaginalis has been understated com-
pared with other medically important human parasitic
protozoans. Pioneering research can be dated back to
1960s, where 100 women affected with refractory tricho-
moniasis were treated using heat-killed T. vaginalis
administered by intravaginal inoculation [15]. The results
showed that clinical symptoms in 89% of vaccinated pa-
tients showed improvement and that T. vaginalis in 40%
of the patients was eliminated [15]. Unfortunately, to our
knowledge, a similar trial has never been repeated to pur-
sue an effective vaccine [16]. Perhaps, this was caused by
the cumbersome approach such as the need to inject dif-
ferent doses of the inactivated T. vaginalis intradermally
into the female cervix, fornix of the vagina and vaginal
wall at 6 to 12 sites [15]. In two preliminary trials, in ani-
mal models, mice were subcutaneously immunized with
whole T. vaginalis cells emulsified in adjuvant and the
results showed some protection in a subsequent vaginal T.
vaginalis challenge [17, 18]. In another study, intranasal
immunization with a 62-kDa proteinase of T. vaginalis
provided sufficient protection in mice [19]. However, until
now, work on the development of T. vaginalis vaccines
has been mainly focused on the screening of potential
immunogens.
The published genome sequence of T. vaginalis will
certainly provide valuable molecular information to better
understand the biology of this pathogen [20]. Alpha-
actinin (TVAG_190450; AF072678.1) is a predicted
115 kDa actin binding protein in T. vaginalis. Its function
mainly involves actin cross-linking and it plays a funda-
mental role in cell motion and morphological changes
[21]. The amoeba-like morphology is required for patho-
genicity and phagocytosis, the latter being an essential
procedure for T. vaginalis ingestion of iron, lipids, nucleo-
tides and other nutrients [22, 23]. To date, it has been
demonstrated that α-actinin is one of the most common
immunogens that can be detected in the sera from women
infected with T. vaginalis [24]. It was also reported that α-
actinin was conserved across numerous T. vaginalis
strains. Thus, when isolated from a single trichomonas
strain, this imunogen could induce corresponding anti-
bodies to different epitopes in different strains [25].
Considering that α-actinin has such an important role
in T. vaginalis survival and high immunogenicity, it shows
great potential to be used in the development of a vaccine
against this parasite. Recently subunit vaccines have be-
come a popular choice in various pathogens due to their
improved avoidance of autoimmunity caused by multiple
antigens evoking molecular mimicry during host defense.
In addition, results have indicated that recombinant sub-
unit vaccines could directly respond to specific molecular
regions conferring protection, indicating that a subunit
vaccine could be a safer and targeted choice [26, 27].
Thus, we tested the truncated α-actinin, including the α-
actinin forepart (ACT-F) and terminal-part (ACT-T), as
subunit immunogens to evaluate their potential in
protecting against T. vaginalis infection. We found that
both ACF-F and ACT-T could confer partial or complete
protection in mice against challenge with T. vaginalis. To
our knowledge, this is the first evidence that demonstrates
the effect of an α-actinin subunit as a vaccine candidate
against T. vaginalis infection in an animal model.
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Methods
Parasites and animals
The Trichmonas vaginalis strain CPOTV21, used in this
work, was isolated from an outpatient in the Second
Affiliated Hospital of Guangzhou Medical University. It
was cryopreserved in liquid nitrogen following axenic
cultivation [28]. The parasite was grown in Diamond’s
Trypticase-yeast medium [29], supplemented with 10%
heat-inactivated fetal bovine serum (Excell, Shanghai,
China), 100 U/ml penicillin, 100 μg/ml streptomycin and
incubated in 5% CO2 at 37 °C. Organisms were subcul-
tured every two days and only the logarithmic-phase
parasites were used in this work.
BALB/C mice (about 6 weeks old) and New Zealand
white rabbits (about 8 weeks old) were purchased from
The Experimental Animal Center of Sun Yat-Sen University
(Guangzhou, China). They were all maintained in pathogen
free conditions and had free access to food and water
according to National Institutes of Health on animal
care and the ethical guidelines. Protocols for the use
of animals were approved by the Institutional Review
Board for Animal Care at Sun Yat-Sen University
(#31472058).
Gene cloning and construction of prokaryotic expression
plasmids
Total RNA from T. vaginalis was extracted with Trizol
reagent (Invitrogen, Carlsbad, USA) following the manu-
facturer’s instructions. After removal of DNA from RNA
with DNase I, the cDNA of T. vaginalis was synthesized
using oligo (dT) primers and the reverse transcription
reaction was conducted by using a primeScript TM RT
reagent Kit (Takara, Dalian, China). The α-actinin fore-
part (ACT-F, 1368 bp, 14–469 aa) and terminal-part
(ACT-T, 1146 bp, 462–844 aa,) were separately amplified
using the following sets of primers, ACT-F-Fw (with
Kpn I site in bold): 5′-GAC GGT ACC GAG AAG ACC
CAG ATC AAG GTT-3′, ACT-F-Rv (with Sal I site in
bold): 5′-AGT GTC GAC GAG GAG GTG CTT GAT
GTA TGT-3′, ACT-T-Fw (with Kpn I site in bold): 5′-
GAC GGT ACC ACA TAC ATC AAG CAC CTC CTC-
3′, ACT-T-Rv (with Sal I site in bold): 5′-AGT GTC
GAC CTT GCA GTA TTC CTT AGC CTG-3′. PCR
amplicons were cloned into expression vector pET-32a
(+) and the construction was then transfected into E. coli
to generate the prokaryotic expression system (BL21-
pET32a-TV-α-actinin). Both recombinant cloning vec-
tors and expression vectors were confirmed by double-
restriction enzyme digestion and nucleotide sequencing.
Expression and purification of recombinant proteins
Conditions that predominantly influenced the expression
of recombinant α- actinin were optimized through set-
ting a series of gradients, which included initial bacterial
density pre-induction, IPTG concentration, induction
time and temperature.
The expressed proteins were purified by the His Tag
Fusion Protein Purification kit, according to manufac-
turer’s instruction (Millipore, Billerica, USA). Electroelu-
tion was also applied for protein purification as previously
described with some changes [30]. Briefly, after SDS-
PAGE was finished and the gel was stained with precooled
0.5 mol/l KCl, target bands were minced and washed from
white to transparent. Electroelution was implemented by
using dialysis bags containing the collected gel in a Tris-
glycin buffer (50 mM Tris-base, 50 mM glycin, 0.1% SDS)
for 4 h. This was followed by electrophoresis at 100 V con-
stant voltage for another 30 min after exchange of the
positive and negative terminals in the electrophoresis ap-
paratus. The purified proteins were then dialyzed in 0.1×
PBS overnight and stored at -80 °C after concentration by
freeze drying.
Western blotting
Samples were resolved by SDS-PAGE and then blotted
onto nitrocellulose membranes. Antigens were probed
by commercial mouse anti-His tag antibodies (1:1000,
Abmart, Shanghai, China) or by our own anti-sera
(1:2,000) collected from rabbits immunized with purified
α- actinin subclones. Horseradish peroxidase (HRP)-la-
belled anti-mouse IgG or Goat anti-rabbit IgG were used
as secondary antibodies (both 1:3,000, Proteintech,
Chicago, USA). The color was developed in the dark
using DAB for 5–10 min and the reaction was stopped
by addition of distilled water.
Immunization schedule and protection from parasite
challenge
New Zealand white rabbits were subcutaneously im-
munized with purified proteins (ACT-F and ACT-T)
for five times (1st, 200 μg emulsified in complete
Freund’s adjuvant; 2nd, 200 μg emulsified in incom-
plete Freund’s adjuvant; 3rd/4th/5th, 100 μg in PBS).
This was carried out at one week intervals for acqui-
sition of rabbit anti-sera against the two parts of the
TV-α-actinin.
BALB/C mice aged 6 weeks old were randomly divided
into seven groups (more than ten in each group), includ-
ing five experimental groups (ACT-F-high dosage, ACT-
F-low dosage, ACT-T-high dosage, ACT-T- Low dosage,
Whole-cell antigen) and two control groups (FA-sham
and unimmunized). All mice in experimental groups
were subcutaneously immunized with a 200 μl volume
of vaccines followed by three boosters within a 2-week
interval (more details are provided in Table 1). For the
FA-sham group, mice were subcutaneously injected with
only PBS in Freund’s adjuvant. Ten days after the last
immunization, three mice from each group were sacrificed
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to detect the splenocyte proliferation and cytokines. The
remaining animals in each group (number is shown in
Fig. 2) were then intraperitoneally challenged with 1 × 107
parasites per mouse. The survival of each individual was
recorded daily over a period of a month. The above de-
scribed immunization experiments were conducted within
two experiments each included both experimental and
control groups.
Indirect immunofluorescence assays
Animals were bled from the tail one day before T. vaginalis
challenge. Sera was collected and stored at -80 °C until use.
Parasites at logarithmic-phase growth were collected by
centrifugation and washed with PBS three times. Half a
million cells in 100 μl were added to poly-L-lysine pre-
coated slides and air-dried at room temperature for
20 min. After fixation with pre-cooled methanol, the slides
were rehydrated with PBS for 20 min and then incubated
with anti-sera (1:2,000) collected from mice with or
without immunization for one hour. After extensive
washes with PBS, another 45 min incubation was under-
taken with goat-anti mouse IgG FITC (1:800; Invitrogen)
and anti-fade mounting medium with DAPI (50 μg/ml)
was conducted. Photos were taken under a fluorescent
microscope (Zeiss, Oberkochen, Germany).
Indirect ELISA for detection of antigen-specific
immunoglobulin and subtypes
One day before each immunization, blood samples of
the mice with or without immunization were collected
and sera were isolated (n = 5). To detect the anti-α-
actinin specific IgG antibodies and IgG isotypes in the
serum samples, indirect ELISA was performed as de-
scribed in a previous study with some changes [9].
Briefly, microtiter plates were coated with recombinant
proteins (2.5 μg/ml, 100 μl/well) for 2 h at 37 °C and
blocked with 5% skimmed milk overnight. The plates
were then incubated with mouse sera, which were ini-
tially diluted at 1:10000 using the half dilution method,
to determine the antibody titers at 37 °C for 2 h. To
show more detail, mouse sera diluted at 1:320,000 were
also incubated with the coated plates for the assessment
of total IgG, and diluted at 1:1,000 and 1:200,000 for
subtype (IgG1 and IgG2) detection.
The plates were then washed with PBS-T for five
times, and the bound antibodies were detected by horse-
radish peroxidase-conjugated goat anti-mouse IgG, IgG1
and IgG2a (Proteintech, Chicago, USA) diluted at 1:3000.
DAB was used to produce the chromogenic reaction and
the value was determined using a microplate reader at OD
450 nm (Mutiskan MK3; Thermo Scientific, Waltham,
USA). The IgG titers were defined as the highest dilution
of sera used when the optical density (OD) values of ex-
perimental groups were at least triple that in the negative
(unimmunized) sera.
Splenocyte proliferation
Ten days after the last immunization, spleens were re-
moved aseptically from three mice of each group and
passed through nylon sieves to obtain splenocytes.
Erythrocytes were removed using NH4Cl-Tris lysis solu-
tion and the splenocytes were resuspended in complete
RPMI-1640 medium supplemented with 10% FBS
(Thermo Fisher, Waltham, USA). Cells were then seeded
onto 96-well plates at a density of 5 × 105 cells per well
and stimulated with antigens dissolved in RPMI-1640 in
a final volume of 200 μl per well and cultured at 37 °C
with 5% CO2. The antigens included recombinant proteins
(ACT-F/ACT-T, 10 μg/ml), concanavalin A (Con A,
5 μg/ml, Sigma-Aldrich) or medium alone (negative con-
trol). The proliferative activity was measured using a Cell
Counting Kit-8 (CCK8, Dojindo laboratories, Kyushu Is-
land, Japan) following the manufacturer’s instructions.
Briefly, after 68 h cultivation, 100 μl of the supernatant
was removed for cytokine assays. Then 10% CCK8 was
added to each well and incubated at 37 °C for 4 h.
Thereafter, the absorbance was evaluated at OD
450 nm using a plate reader (Mutiskan MK3; Thermo
Fisher). The stimulation index (SI) was calculated as
the ratio of the average OD 450 value of wells
Table 1 Immunization protocol in experimental and control groups
Groups Groups (No. of animals) 1st (0w) 2nd (2w) 3rd (4w) 4th (6w)
High dosage (μg) ACT-F (14) 100 100 100 100
ACT-T (15) 100 100 100 100
Low dosage (μg) ACT-F (13) 40 20 20 20
ACT-T (18) 40 20 20 20
Whole-cell antigen (13)a 40 20 20 20
Control (μl) FA-sham (14)b 200 200 200 200
Unimmunized (20)c 200 200 200 200
aT. vaginalis was made into whole-cell antigen by sonication and alternate freeze/thaw treatment (in liquid nitrogen and 37 °C). The whole-cell antigen was
quantified by using a Bicinchoninic Acid Kit (BCA). Before vaccination, it was emulsified in Freund’s adjuvant
bEach mouse, 100 μl PBS emulsified in 100 μl completed Freund’s adjuvant for the 1st immunization, in incomplete Freund’s adjuvant for 2nd, 3rd and 4th immunizations
cEach mouse was injected with only 200 μl sterile PBS using the same procedure in other groups
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containing antigen-stimulated cells to the average OD
450 value of wells containing only cells with medium.
All assays were performed in triplicate.
Cytokine assays
For the assessment of cytokines produced by activated
splenocytes, the concentration of IL-2, IL-4, IL-6, IFN-γ,
IL-17A and IL-10 was determined by using Cytometric
Bead Array (CBA) (BD Biosciences, New Jersey, USA).
Briefly, according to the manufacturer’s instructions,
50 μl mixture of capturing beads was mixed with 50 μl
of supernatant from splenocyte proliferation assay after
68 h cultivation, and then 50 μl of Mouse-PE detection
reagent was added for detection. Ten concentration gra-
dients of cytokine standards were used for plotting the
standard curve. Mixed samples were incubated for 3 h at
room temperature away from light, then washed, centri-
fuged at 200× g for 5 min and subsequently analyzed in
the FACScan flow cytometer (BD Biosciences). Each sam-
ple was analyzed in duplicate and each group included
three mice.
Statistical analysis
The graphics, including antibody responses, lymphopro-
liferation assays and cytokine production levels, were
made by using GraphPad Prism 5 software. Statistical
significance on the comparison of mean values and SEM
was assessed by independent sample t-test performed
using Statistical Package for the Social Sciences (SPSS)
version 22.0, IBM. Statistical significance was accepted
at P < 0.05.
Results
Expression of two α-actinin peptides
The coding regions of α-actinin (ACT-F, 14–469 aa and
ACT-T, 462–844 aa) were amplified from cDNA and
cloned into pET-32a (+) expression vector by insertion
at Kpn I/Sal I restriction sites. An attempt was made to
keep each subsection of α-actinin an equal length but
also containing parts with the predicted highest antige-
nicity region (amino acid 377 to 382, 409 to 414, and
682 to 687) [21]. After confirmation by double digestion
and sequencing, constructs were transfected into BL21
cells. A clear expression of both proteins (70.33 kDa of
ACT-F and 61.7 kDa of ACT-T) was achieved by initial
induction of the log-phase bacteria (OD 600 nm = 0.8)
with IPTG (0.6 mmol/l), at 24 °C for 5 h (Fig. 1a). After
Ni-NTA based purification and/or electroelution, we
harvested reasonably pure peptides. Western blot by
anti-His antibody or anti-sera collected from rabbits
immunized with purified proteins confirmed that the
peptides were ACT-F and ACT-T (Fig. 1b).
Protective effect of recombinant antigens
The protective efficacy of the recombinant antigens as
potential vaccines against T. vaginalis infection was
investigated in BALB/C mice. Each mouse received one
primary vaccination and three boosters (Table 1),
followed by an intraperitoneal injection of 1 × 107 T.
vaginalis trophozoites.
Our data showed that immunization with high dosage
of ACT-T gave complete protection to the animals,
because 100% of the animals survived for over a month
post-infection until they were sacrificed (Fig. 2). In
the other four experimental groups, only partial
protection (20–55%) was provided by vaccination. For
example, the degree of protection was 55% in the
ACT-F-high dosage group, 40% in the ACT-T-low
dosage group, 42% in the ACT-F-low dosage group
and 20% in the whole-cell antigen group. While in
Fig. 1 Prokaryotic expression and purification of α-actinin. a SDS-PAGE
analysis of prokaryotic expression of recombinant α-actinin peptides
(ACT-F and ACT-T). IPTG-, non-induced; IPTG+, 0.6 mM IPTG induced
for 4 h; purified, after electroelution purification. b Western blotting
analysis using anti-His tag monoclonal antibody (at 1:1,000 dilution)
and sera containing rabbit anti-sera (at 1:2,000 dilution). ACT-F,
70.33 kDa; ACT-T, 61.7 kDa
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the FA-sham and unimmunized groups, most mice
(83–89%) were dead within ten days.
Level of immunoglobulin isotypes in serum samples
As the high-dosage immunization groups provided a
better protection against T. vaginalis infection, the
following assessment of vaccine potency only focused on
these groups. To determine if a systemic immune
response could be stimulated by immunization, a set of
mouse sera (5 mice per group) were collected. These
were taken at weeks 0, 2, 4, 6 and 8, one day before each
scheduled immunization and used for the detection of
the α-actinin specific immunoglobulin IgG. As indicated
in Fig. 3a, both the recombinant proteins (ACT-F and
ACT-T) could induce a high titer of IgG in BALB/C
mice.
The IgG titer could be detected at two weeks after the
primary immunization and reached a peak only if mice
received another booster injection (at the 4th week)
(Fig. 3a). This indicated that a total of two vaccinations
may be enough for protection. While an OD 450 nm
value of serum IgG at 1:320000 dilution gradually in-
creased with each vaccination (Fig. 3b). As expected,
sera collected from the mice in FA-sham and unimmu-
nized groups were negative, showed no specific antibody
titer and displayed a background level of the OD 450
value even at a 1:500 dilution (Fig. 3b).
The OD 450 values of the ACT-F-high dosage and
ACT-T-high dosage specific IgG1 (Fig. 3c, d) in the
vaccinated mice were significantly higher than that in
the unimmunized (ACT-F: t(4) = -7.105, P = 0.002; ACT-
T: t(4.003) = -146.210, P < 0.0001) and sham FA-sham
groups (ACT-F: t(4.001) = -7.087, P = 0.002; ACT-T:
t(4.197) = -144.152, P < 0.0001), which were seen only at a
Fig. 2 Assessment of protective potency of α-actinin peptide vaccines
in mice. BALB/C mice were immunized with ACT-F (high, n = 11; low,
n = 12), ACT-T (high, n = 10; low, n = 15), whole-cell antigen (n = 10),
PBS in adjuvant (FA-sham; n = 11), unimmunized (n = 17) and followed
by intraperitoneal challenge with T. vaginalis (1 × 107 per mouse) two
weeks after last immunization. Mice were monitored daily to obtain
the survival percentage
Fig. 3 Levels of IgG in the sera of mice immunized with specific antigens. a Total IgG titers exhibited, (b-d) total IgG (at 1:320,000 dilution), IgG
subclasses (at 1:1,000 and 1:200,000 dilution) determined by OD450 nm value in the mice sera collected one day before each immunization as
indicated. Each bar represents the mean value ± standard error (SEM) (n = 5). Significance was accepted by comparison with the unimmunized
group (*P < 0.05; **P < 0.01; ***P < 0.001) or FA-sham group (#P < 0.05; ##P < 0.01; ###P < 0.001) using statistical analyses
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background level. The high levels of IgG1 compared
with IgG2a (ACT-F: t(8) = 5.321, P = 0.001; ACT-T:
t(8) = 50.741, P < 0.0001) in each experimental group
indicated that the humoral immunization elicited by
these two peptides was a mix of Th1 and Th2
responses but predominantly biased towards the Th2
response (Fig. 3c, d).
Anti-sera generated recognized α-actinin
Immunofluorescence assays were performed to assess
whether anti-sera against α-actinin could recognize the
native protein in T. vaginalis trophozoites. Diluted im-
mune sera (1:1,000) and pre-immune sera from mice
were incubated with fixed parasites and were further
reacted with goat-anti mouse IgG FITC and DAPI.
According to other research, intracellular α-actinin is
located throughout the cytoplasm [21]. Our study
showed that, when probed with immune sera from the
two protein-immunized groups, the native α-actinin
could be detected as being diffusely distributed in the
cytoplasm (Fig. 4c, d). However, it was not detected in
control groups treated with the pre-immune or FA-sham
sera (Fig. 4a, b). This recognition may support the
possibility that specific antibodies could also recognize
α-actinin of T. vaginalis in vivo to further mediate anti-
body dependent cytotoxicity.
Splenocyte proliferation assay
To further assess the immune responses, splenocytes
were removed from mice in each group and proliferation
was measured upon stimulation with corresponding
ACT-F and ACT-T proteins (10 μg/ml) in response to
immunization. As shown in Fig. 5, almost no increase in
proliferation (approximate stimulation index, SI = 1.0)
was detected in splenocytes from mice in unimmu-
nized and FA-sham groups after stimulation with ei-
ther ACT-F or ACT-T. While for splenocytes from
mice immunized with high dosages of ACT-F or
ACT-T, significant increases in stimulation index (SI)
were observed with re-exposure to either ACT-F
(ACT-F vs FA-sham: t(4) = -4.793, P = 0.009) or ACT-T
(ACT-T vs FA-sham: t(4) = -14.897, P < 0.0001). The
proliferation of lymphocytes in samples indicated that
immune memory responses were present and might
play a protective function against parasites with the
same antigens. In addition, after treatment with ConA
Fig. 4 Native α-actinin in T. vaginalis was recognized by serum from immunized mice. Immunofluorescence of native parasite α-actinin detected
with mouse sera (at 1:2,000 dilution) from different groups: a T. vaginalis were incubated with pre-immunized mouse serum; b T. vaginalis were
incubated with serum from FA-sham immunized mice; c T. vaginalis were incubated with serum from high dosage ACT-F immunized mice;
d T. vaginalis were incubated with serum from high dosage ACT-T immunized mice serum. Goat-anti mouse IgG FITC (at 1:800 dilution) was
used as secondary antibody. T. vaginalis α-actinin was labeled with FITC (in green) and DNA was stained with DAPI (in blue). Scale-bar: 10 μm
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(10 μg/ml, positive control), splenocytes from mice in
all groups proliferated to comparable levels as those being
stimulated with ACT-F and ACT-T (SI = 1.67–2.34).
Cytokine expression
After the splenocyte proliferation assays were carried
out, cytokine secretion in the supernatants was tested.
As indicated in Fig. 6, in vitro treatment of spleno-
cytes from the high dosage ACT-T vaccinated mice
with ACT-T triggered significantly higher amounts of
pro-inflammatory cytokines such as IFN-γ (36.7 fold;
FA-sham, 3.41 pg/ml; ACT-T, 125 pg/ml; t(4) = -3.734,
P = 0.02), IL-17A (6.34 fold; FA-sham, 17.2 pg/ml;
ACT-T, 109 pg/ml; t(10) = -4.31, P = 0.002) and IL-6
(3.57 fold; FA-sham, 88.1 pg/ml; ACT-T, 314 pg/ml;
t(5.084) = -3.011, P = 0.029). While mice immunized
with the high dosage of ACT-F, splenocytes pretreated
with ACT-F could also secrete significantly high levels
of IFN-γ (20.3 fold; FA-sham, 4.63 pg/ml; ACT-F, 94.2 pg/
ml; t(5.015) = -10.289, P < 0.0001), IL-17A (8.81 fold; FA-
sham, 16.8 pg/ml; ACT-F, 148 pg/ml; t(5.179) = -5.157, P =
0.003) and IL-6 (5.74 fold; FA-sham, 122 pg/ml; ACT-F,
700 pg/ml; t(10) = -13.46, P < 0.0001) when compared with
unimmunized and FA-sham groups, which only produced
background levels of these cytokines (Fig. 6). As a marker
for the Th2 response, IL-10 detection was increased
significantly in the mice vaccinated with high dosage of
ACT-T (3.94 fold; FA-sham, 69.0 pg/ml; ACT-T,
272 pg/ml; t(5.309) = -3.428, P = 0.017) and high dosage
of ACT-F (1.71 fold; FA-sham, 115 pg/ml; ACT-F,
197 pg/ml; t(10) = -3.923, P = 0.003) respectively. This
might be caused by the requirement for an immune
Th1/Th2 balance in vivo for host self-protection [31].
In response to ConA, the positive control, high
levels of the above-mentioned cytokines were detected
in the splenocytes isolated from animals in all groups
(data not shown). Interestingly, however, as common
markers of Th1 (IL-2) and Th2 (IL-4) immune re-
sponses, only barely detectable levels of IL-2 (4.87–
21.3 pg/ml) and IL-4 (4.20–21.3 pg/ml) were seen in
cells from all groups after restimulation in vitro.
Fig. 5 Proliferation analysis of splenocytes from immunized mice in
vitro. Splenocytes from ACT-F- high dosage, ACT-T- high dosage, FA-
sham (PBS in adjuvant) and unimmunized groups were stimulated with
ACT-F or ACT-T (10 μg/ml) for 68 h in vitro. Proliferation was
determined using CCK8 cell counting kits. The stimulation index (SI)
is calculated as the ratio of the proliferation of stimulated cells to
non-stimulated cells in the same group. The data are the mean SI ± SEM
from three individual mice from each group with three repeats (n= 3).
Significance was accepted by comparison with the unimmunized
(*P< 0.05; **P< 0.01; ***P< 0.001) and FA-sham groups (#P< 0.05;
##P< 0.01; ###P< 0.001) using statistical analyses
Fig. 6 Cytokine secretion of splenocytes from immunized mice. Cytokines in supernatants were assayed in duplicate using CBA Kits (n = 3). The
data are shown as mean value ± standard error (SEM) for antigen treatment. Significance was calculated by comparison with the unimmunized
group (*P < 0.05; **P < 0.01; ***P < 0.001) or the FA-sham group (#P < 0.05; ##P < 0.01; ###P < 0.001) using statistical analyses
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Discussion
For prevention and control of infectious diseases,
vaccines are usually considered the most cost-efficient
tools to block the transmission of pathogens [32].
However, the search for candidate antigens is one of the
most difficult steps in the process. Several reports have
suggested α-actinin of T. vaginalis as a candidate for
the development of effective vaccines against this
parasite [7, 16, 24].
Alpha-actinin, both native and recombinant, can be
recognized by sera from women who have been exposed
to T. vaginalis. It has been proved to be the most com-
mon immunogen with high immunogenicity [9, 24, 33],
an essential requirement as a vaccine candidate [32].
Additionally, there is a very low similarity in amino acid
sequences of the epitopes between T. vaginalis α-actinin
and the corresponding human actinin homolog [21, 34].
This could avoid the possibility of autoimmunity caused
by epitope similarity in humans. Most importantly, as a
structural protein, α-actinin is constantly expressed dur-
ing the entire life-cycle of T. vaginalis and is present in
all isolates despite geographic variation [24]. Therefore,
these broadly positive characteristics make the develop-
ment of α-actinin as a candidate vaccine inspiring and
meaningful.
For the assessment of a vaccine candidate, protective
efficacy in vivo is one of the most important parameters
[32]. As a commonly used method in parasitology for
measuring protective efficacy, the survival rate of vacci-
nated animals after challenge with pathogens (in this
case, T. vaginalis) is a direct parameter. Our results
showed that immunization with a high dose of ACT-T
gave complete protection with 100% animals immunized
surviving for over a month post-infection until the
experiment was terminated (Fig. 2). Comparatively, low-
dosage ACT-T or ACT-F also provided a protective
effect (40% or 42%, respectively) that was still higher
than those immunized with whole-cell antigen (20%).
These results indicated that these recombinant proteins
showed higher protective potency than whole-cell antigen
in our mouse model. The results also clearly demonstrate
that both ACT-F and ACT-T, but particularly the high
dosage ACT-T, could significantly protect mice from the
challenge by T. vaginalis. This strongly supports the
suggestion that α-actinin could be a candidate for the
development of an effective vaccine against T. vagina-
lis [7, 16, 24].
Previously, there have been some attempts to develop
vaccines against T. vaginalis [17, 18]. Of which, two
studies relied on a whole-cell T. vaginalis vaccine given
by subcutaneous immunization and vaginal challenge of
T. vaginalis in mice. Although 72–100% protection was
found, it could be questioned as to whether their infection
was initially successful. Remarkably, in their detection at
one month after T. vaginalis infection, the parasite was
not detected in 39–53% of the mice in their unimmunized
group [17, 18]. This means that nearly half of the mice
could, without any vaccination, either eliminate T. vagina-
lis in their vaginas directly and/or have failed to get a
successful infection. Their results indicated that the model
of vaginal inoculation with T. vaginalis, even with pre-
treatment of Lactobacillus acidophilus and estradiol
valerate in the mouse vagina, may provide inconsistent
infection rates (in this case varying from 47–61%) [17, 18].
Additionally, in their studies, parasites were not recovered
in 43% of the mice in the FA-sham group or 80% of the
mice in the Alum-sham group. It seemed that the adju-
vants, especially Alum, as opposed to the whole-cell T.
vaginalis, mainly played the protective function. It is
obvious that the mouse model, using vaginal infection,
can’t mimic and be considered a suitable model to evalu-
ate the effect of vaccines against T. vaginalis infection. In
fact, this model not only provides unreliable results com-
pared to our current study but reliance on it also limits
the progress of related research.
In contrast, in our current study, almost 90% of the
mice died in the Freund’s adjuvant-sham (FA-sham) and
unimmunized groups within 10 days after intraperitoneal
challenge with 1 × 107 T. vaginalis. This clearly indicated
a high and guaranteed initial infection in our intraperito-
neal mouse model. Intraperitoneal inoculation of the
parasite in mice is a common model for detection of
virulence of T. vaginalis isolates or for screening of
trichomonacidal compounds [35, 36]. In our under-
standing, this model also mimics a natural migration of
T. vaginalis to the peritoneal cavity causing ascites,
which has been reported in patients [37, 38]. Import-
antly, the intraperitoneal infection model has also been
used in other relevant studies for vaccine candidate
assessment [39].
Therefore, we consider that it is a reliable model for vac-
cine development against T. vaginalis with the following
advantages: (i) Clinical signs in the animal, such as curling
up, lack of vitality, decreased appetite, piloerection in fur,
sloth and weight loss, could be clearly observed. Almost
all mice without vaccination with α-actinin died within
10 days post-inoculation of T. vaginalis strain CPOTV21,
which makes it easier to evaluate the protection of the
potential proteins. (ii) Several years experience in our
laboratory has demonstrated that the mouse peritoneal
cavity is an ideal place for T. vaginalis growth compared
with the traditional mouse vagina. (iii) The intraperitoneal
inoculation model was convenient to operate and guaran-
teed infection, while the intravaginal model is time con-
suming and involves a complicated pretreatment process.
For example, it requires pretreatment of the mouse vagina
with estrogen and L. acidophilus to establish a sustainable
infection and it requires rinses to collect the living
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parasites before each examination of infection [40].
Despite the pretreatment, infection ratios of 47 to 61% in
the intravaginal model were still low and therefore it should
not be considered a suitable animal model for vaccine de-
velopment and anti-trichomonas compound screening.
To further evaluate the vaccine potency of our proteins,
important parameters were assessed including measuring
the humoral immune response status, T lymphocyte pro-
liferation capability and cellular immune response status.
We found that both ACT-F and ACT-T could induce a
mixed Th1/Th2 response with a high level of specific IgG
but with Th2-bias isotypes (IgG1 > IgG2) in mice (Fig. 3c).
This indicates that they are highly immunogenic proteins.
This is in accordance with the results from other labora-
tories [17–19], from which a prominent increase of IgG1
was also detected. However, although T. vaginalis anti-
bodies were frequently detected in patients, protection by
these immunoglobulins was not found [25, 41, 42]. There-
fore, to our knowledge, the exact function of immuno-
globulins in host protection against T. vaginalis remains
unclear. Based on our results, the high antibody titers and
protection found in the mice immunized with high dosage
of ACT-T and the lesser effect with low dosage of ACT-T
indicate that the protection against T. vaginalis infection
may possibly link with humoral responses, at least in part.
There is no doubt that besides the humoral responses,
the cellular immune response is also an important index
for assessing the immunogenicity of vaccine candidates.
For this purpose, the level of cytokines in the super-
natant of lymphocyte cultures from spleen following
immunization and re-stimulation in vitro is usually one
of the detectable marker systems. Cytokines released by
lymphocytes, especially the Th1-type (e.g. IFN-γ) play an
important function in host protection against many
pathogen infections including T. vaginalis [43]. Our
results also demonstrated that significantly higher
levels of IFN-γ were detected in the animals vacci-
nated with ACF-F or ACT-T than those from the
controls which were in accord with the protection
rate seen. In fact, IFN-γ has been proved to increase
macrophage-mediated cytotoxity against T. vaginalis
[44, 45]. Of which the monocyte-macrophage lineage
has been identified as an important lineage involved
in T. vaginalis killing in vivo [46]. In other studies,
IFN-γ has also been considered to play a role in the
elimination or suppression of proliferation of T. vagi-
nalis [43–45] by stimulation of nitric oxide produc-
tion as one of the effectors [44, 45].
IL-17, another crucial proinflammatory factor, was also
found to be significantly increased in splenocytes from
the animals immunized with ACF-F/T in our work.
Although the role of IL-17 is poorly understood dur-
ing T. vaginalis infection, data from patients infected
with T. vaginalis [47] and our work indicated that IL-
17 could be involved in protection. As a matter of
fact, IL-17 has been shown to play important roles in
host responses against pathogens like Entamoeba his-
tolytica [48] and some bacterial infections [49, 50].
These IL-17-mediated protective effects may function
by a direct or indirect regulation of Th1 responses, den-
dritic cells and neutrophils [48–51]. Of them, neutrophils
have been shown to be a major host protector during T.
vaginalis infection either through a complement-mediated
and IgG-enhanced pathway or by the myeloperoxidase
and superoxide anion cytotoxity pathways [52–54]. IL-17
is a key cytokine for the activation, recruitment, and mi-
gration of neutrophils to the inflammation sites [55, 56]. It
is likely, therefore, that the observed increase in IL-17 in
the animals vaccinated with ACT is likely to be involved
in a protective role, through the neutrophil-dependent
mechanism, in trichomoniasis. Obviously, further research
is required before we can better understand the mechan-
ism of action of this cytokine in T. vaginalis infection.
Conclusions
In summary, the present study demonstrated that a high
dose of recombinant T. vaginalis α-actinin fragments,
derived from ACT-F and ACT-T, could induce a mixed
(Th1/Th2) humoral and cellular immune response and
provide 48% and 100% protection in mice through
multifaceted mechanisms. These results strongly support
the view that α-actinins, which are characterized by
high immunogenicity, high antigen specificity and well
conserved immunogenic epitopes, are strong potential
vaccine candidates against T. vaginalis infection.
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